Browse all articles in Featured

Remote treatment of patients with long-term conditions, including cardiovascular disease and stroke, could yield considerable NHS savings through reducing hospital admissions, according to results revealed recently by Birmingham OwnHealth from their ongoing telehealth programme.

A recent study,¹ published in the Journal of the American College of Cardiology, confirms that parental history of cardiovascular disease nearly doubles a person’s risk in all regions of the world, even after considering all other known risk factors.

The impact of air pollution on cardiac health is the subject of research recently published in The Lancet,¹ aiming to estimate the burden of disease generated worldwide by exposure to second-hand smoke. This was calculated from disease-specific relative risk estimates and area-specific estimates of the proportion of people exposed, by comparative risk-assessment methods, with data from 192 countries during 2004.

The lives of thousands of patients with atrial fibrillation (AF) could be at risk due to poor diagnosis, failure to follow treatment guidelines and lack of quality information for AF patients, warns a report[1] published recently by the AF AWARE partnership*.

October 3rd – 6th 2010 saw over 1,500 delegates descend upon the Birmingham Metropole Hilton Hotel for this year’s Heart Rhythm Congress (HRC). This report examines some of the highlights of this ever more popular meeting.

Atrial Fibrillation, Myocardial Revascularisation and Devices For Heart Failure.

The Heart Rhythm Society Convention is the largest cardiac electrophysiology meeting in the world attracting thousands of participants and experts from around the globe.

This report, by Dr Benedict M Glover (Senior Cardiac Electrophysiology Fellow) summarises the key elements of the convention focusing on late breaking trials, live cases and important developments.

Now in its seventh year, Arrhythmia Awareness Week (AAAW) has been instrumental in helping to highlight heart rhythm disorders and work towards improving the diagnosis and treatment of this once largely overlooked area.

The first implantation of the now commercially available Advisa DR MRI™ SureScan™ pacing system has taken place in United Kingdom (UK).

Advisa MRI is Medtronic’s second-generation pacing system in a portfolio of pacing systems designed, tested, and approved for use as labeled with MRI machines in UK.

Data from a post-hoc analysis presented today at the 59th Annual Scientific Session of the American College of Cardiology in Atlanta, Georgia, evaluated transition to Multaq® (dronedarone) in patients with atrial fibrillation (AF) or atrial flutter (AFL) following prior treatment with amiodarone.